FY2027 Earnings Forecast for VRTX Issued By Erste Group Bank

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Investment analysts at Erste Group Bank issued their FY2027 earnings per share (EPS) estimates for shares of Vertex Pharmaceuticals in a note issued to investors on Wednesday, February 18th. Erste Group Bank analyst H. Engel expects that the pharmaceutical company will earn $19.31 per share for the year. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm’s revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the firm earned $3.98 EPS.

VRTX has been the topic of a number of other research reports. Morgan Stanley reissued an “overweight” rating and set a $570.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Leerink Partners lifted their price target on Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a research report on Monday, December 29th. Royal Bank Of Canada cut their price objective on Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating for the company in a report on Friday, February 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $590.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Finally, UBS Group boosted their price target on shares of Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Twenty-two analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $542.00.

Vertex Pharmaceuticals Stock Up 1.6%

VRTX stock opened at $476.90 on Monday. The company has a 50-day simple moving average of $463.26 and a 200 day simple moving average of $428.83. The company has a market capitalization of $121.15 billion, a P/E ratio of 31.11 and a beta of 0.30. Vertex Pharmaceuticals has a fifty-two week low of $362.50 and a fifty-two week high of $519.68.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Jonathan Biller sold 1,925 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $886,327.75. Following the sale, the executive vice president owned 20,819 shares in the company, valued at approximately $9,585,692.17. The trade was a 8.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Mark E. Bunnage sold 2,021 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $930,529.03. Following the sale, the executive vice president owned 12,914 shares in the company, valued at approximately $5,945,993.02. The trade was a 13.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 100,852 shares of company stock valued at $45,787,299 over the last ninety days. Company insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Chesapeake Asset Management LLC boosted its stake in Vertex Pharmaceuticals by 110.0% in the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 33 shares during the period. Motiv8 Investments LLC purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at $26,000. Access Investment Management LLC acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter worth $27,000. Colonial Trust Co SC grew its holdings in shares of Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 38 shares in the last quarter. Finally, Swiss RE Ltd. acquired a new position in Vertex Pharmaceuticals during the fourth quarter valued at $28,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.